Boston Scientific has completed first patient enrolment in a prospective randomised international neural cardiac therapy for heart failure (NECTAR-HF) clinical trial.
The clinical feasibility study will evaluate 96 patients with vagal nerve stimulator implants to study the preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The first implants in the trial took place at Hospital Clinic in Barcelona, Spain.
Barcelona’s Hospital Clinic medical director Josep Brugada said NECTAR-HF will investigate whether vagal nerve stimulation can restore autonomic balance and therefore improve heart function, increase exercise capacity and inhibit progression of heart failure.
Boston Scientific Cardiac Rhythm Management chief medical officer Kenneth Stein said this novel technology utilises Boston Scientific’s capabilities in cardiac rhythm management device therapy, lead technologies and neuromodulation.
”This treatment capability illustrates our strategy to offer new therapies in high-potential markets that are designed to improve the quality of life for patients," Stein added.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
